Depression-Pipeline Review, H1 2017

Depression-Pipeline Review, H1 2017


  • Products Id :- GMDHC9171IDB
  • |
  • Pages: 476
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Depression-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression-Pipeline Review, H1 2017, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 14, 27, 23, 74, 15 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 17 and 8 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 7

Depression-Overview 8

Depression-Therapeutics Development 9

Depression-Therapeutics Assessment 33

Depression-Companies Involved in Therapeutics Development 49

Depression-Drug Profiles 97

Depression-Dormant Projects 427

Depression-Discontinued Products 441

Depression-Product Development Milestones 446

Appendix 456

List of Figures

Number of Products under Development for Depression, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Depression, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Depression-Pipeline by 4D Pharma PLC, H1 2017

Depression-Pipeline by AB Science SA, H1 2017

Depression-Pipeline by Acadia Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Adamed Sp z oo, H1 2017

Depression-Pipeline by Addex Therapeutics Ltd, H1 2017

Depression-Pipeline by Aequus Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Alkermes Plc, H1 2017

Depression-Pipeline by Allergan Plc, H1 2017

Depression-Pipeline by Alvogen Korea Co Ltd, H1 2017

Depression-Pipeline by Amorsa Therapeutics Inc, H1 2017

Depression-Pipeline by Anavex Life Sciences Corp, H1 2017

Depression-Pipeline by Angelini Group, H1 2017

Depression-Pipeline by Angita BV, H1 2017

Depression-Pipeline by Araim Pharmaceuticals Inc, H1 2017

Depression-Pipeline by AstraZeneca Plc, H1 2017

Depression-Pipeline by Avanir Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Axsome Therapeutics Inc, H1 2017

Depression-Pipeline by Azevan Pharmaceuticals Inc, H1 2017

Depression-Pipeline by BioCrea GmbH, H1 2017

Depression-Pipeline by BioLite Inc, H1 2017

Depression-Pipeline by Bionomics Ltd, H1 2017

Depression-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Depression-Pipeline by Bristol-Myers Squibb Company, H1 2017

Depression-Pipeline by Calico LLC, H1 2017

Depression-Pipeline by Celgene Corp, H1 2017

Depression-Pipeline by Celon Pharma SA, H1 2017

Depression-Pipeline by Cerecor Inc, H1 2017

Depression-Pipeline by Clera Inc, H1 2017

Depression-Pipeline by Delpor Inc, H1 2017

Depression-Pipeline by Domain Therapeutics SA, H1 2017

Depression-Pipeline by Eisai Co Ltd, H1 2017

Depression-Pipeline by Eli Lilly and Company, H1 2017

Depression-Pipeline by Evotec AG, H1 2017

Depression-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Depression-Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017

Depression-Pipeline by FPRT Bio Inc, H1 2017

Depression-Pipeline by GlaxoSmithKline Plc, H1 2017

Depression-Pipeline by GliaCure Inc, H1 2017

Depression-Pipeline by H. Lundbeck A/S, H1 2017

Depression-Pipeline by Heptares Therapeutics Ltd, H1 2017

Depression-Pipeline by Hua Medicine (Shanghai) Ltd, H1 2017

Depression-Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Depression-Pipeline by Impel NeuroPharma Inc, H1 2017

Depression-Pipeline by INSYS Therapeutics Inc, H1 2017

Depression-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Depression-Pipeline by Intra-Cellular Therapies Inc, H1 2017

Depression-Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Johnson & Johnson, H1 2017

Depression-Pipeline by KemPharm Inc, H1 2017

Depression-Pipeline by Lead Discovery Center GmbH, H1 2017

Depression-Pipeline by Les Laboratoires ServierSAS, H1 2017

Depression-Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Depression-Pipeline by Luye Pharma Group Ltd, H1 2017

Depression-Pipeline by Mapi Pharma Ltd, H1 2017

Depression-Pipeline by Mapreg SAS, H1 2017

Depression-Pipeline by Medlab Clinical Ltd, H1 2017

Depression-Pipeline by Meta-IQ ApS, H1 2017

Depression-Pipeline by Methylation Sciences Inc, H1 2017

Depression-Pipeline by miCure Therapeutics Ltd, H1 2017

Depression-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Depression-Pipeline by Navya Biologicals Pvt Ltd, H1 2017

Depression-Pipeline by Neuralstem Inc, H1 2017

Depression-Pipeline by Neurocrine Biosciences Inc, H1 2017

Depression-Pipeline by NeuroNascent Inc, H1 2017

Depression-Pipeline by NeurOp Inc, H1 2017

Depression-Pipeline by Newron Pharmaceuticals SpA, H1 2017

Depression-Pipeline by Nippon Chemiphar Co Ltd, H1 2017

Depression-Pipeline by nLife Therapeutics SL, H1 2017

Depression-Pipeline by Omeros Corp, H1 2017

Depression-Pipeline by Orexigen Therapeutics Inc, H1 2017

Depression-Pipeline by Otsuka Holdings Co Ltd, H1 2017

Depression-Pipeline by Pfizer Inc, H1 2017

Depression-Pipeline by Pherin Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Polleo Pharma Ltd, H1 2017

Depression-Pipeline by Protagenic Therapeutics Inc, H1 2017

Depression-Pipeline by Relmada Therapeutics Inc, H1 2017

Depression-Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Richter Gedeon Nyrt, H1 2017

Depression-Pipeline by Sage Therapeutics Inc, H1 2017

Depression-Pipeline by Saniona AB, H1 2017

Depression-Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Depression-Pipeline by Sound Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Depression-Pipeline by Supernus Pharmaceuticals Inc, H1 2017

Depression-Pipeline by Suven Life Sciences Ltd, H1 2017

Depression-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017

Depression-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Depression-Pipeline by Tetra Discovery Partners LLC, H1 2017

Depression-Pipeline by Trevena Inc, H1 2017

Depression-Pipeline by TRImaran Pharma Inc, H1 2017

Depression-Pipeline by VistaGen Therapeutics Inc, H1 2017

Depression-Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd, H1 2017

Depression-Pipeline by Zogenix Inc, H1 2017

Depression-Pipeline by Zysis Ltd, H1 2017

Depression-Dormant Projects, H1 2017

Depression-Dormant Projects, H1 2017 (Contd..1), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..2), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..3), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..4), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..5), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..6), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..7), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..8), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..9), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..10), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..11), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..12), H1 2017

Depression-Dormant Projects, H1 2017 (Contd..13), H1 2017

Depression-Discontinued Products, H1 2017

Depression-Discontinued Products, H1 2017 (Contd..1), H1 2017

Depression-Discontinued Products, H1 2017 (Contd..2), H1 2017

Depression-Discontinued Products, H1 2017 (Contd..3), H1 2017

Depression-Discontinued Products, H1 2017 (Contd..4), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4D Pharma PLC, AB Science SA, Acadia Pharmaceuticals Inc, Adamed Sp z oo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Alkermes Plc, Allergan Plc, Alvogen Korea Co Ltd, Amorsa Therapeutics Inc, Anavex Life Sciences Corp, Angelini Group, Angita BV, Araim Pharmaceuticals Inc, AstraZeneca Plc, Avanir Pharmaceuticals Inc, Axsome Therapeutics Inc, Azevan Pharmaceuticals Inc, BioCrea GmbH, BioLite Inc, Bionomics Ltd, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Calico LLC, Celgene Corp, Celon Pharma SA, Cerecor Inc, Clera Inc, Delpor Inc, Domain Therapeutics SA, Eisai Co Ltd, Eli Lilly and Company, Evotec AG, F. Hoffmann-La Roche Ltd, Fabre-Kramer Pharmaceuticals Inc, FPRT Bio Inc, GlaxoSmithKline Plc, GliaCure Inc, H. Lundbeck A/S, Heptares Therapeutics Ltd, Hua Medicine (Shanghai) Ltd, Hyundai Pharmaceutical Co Ltd, Impel NeuroPharma Inc, INSYS Therapeutics Inc, Intas Pharmaceuticals Ltd, Intra-Cellular Therapies Inc, INVENT Pharmaceuticals Inc, Johnson & Johnson, KemPharm Inc, Lead Discovery Center GmbH, Les Laboratoires ServierSAS, Lixte Biotechnology Holdings Inc, Luye Pharma Group Ltd, Mapi Pharma Ltd, Mapreg SAS, Medlab Clinical Ltd, Meta-IQ ApS, Methylation Sciences Inc, miCure Therapeutics Ltd, Mitsubishi Tanabe Pharma Corp, Navya Biologicals Pvt Ltd, Neuralstem Inc, Neurocrine Biosciences Inc, NeuroNascent Inc, NeurOp Inc, Newron Pharmaceuticals SpA, Nippon Chemiphar Co Ltd, nLife Therapeutics SL, Omeros Corp, Orexigen Therapeutics Inc, Otsuka Holdings Co Ltd, Pfizer Inc, Pherin Pharmaceuticals Inc, Polleo Pharma Ltd, Protagenic Therapeutics Inc, Relmada Therapeutics Inc, Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt, Sage Therapeutics Inc, Saniona AB, SK Biopharmaceuticals Co Ltd, Sound Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Supernus Pharmaceuticals Inc, Suven Life Sciences Ltd, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Company Ltd, Tetra Discovery Partners LLC, Trevena Inc, TRImaran Pharma Inc, VistaGen Therapeutics Inc, Zhejiang Huahai Pharmaceutical Co Ltd, Zogenix Inc, Zysis Ltd

select a license

Single User License
USD 2000 INR 128520
Site License
USD 4000 INR 257040
Corporate User License
USD 6000 INR 385560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com